Freeze-Drying Process Optimisation for a Small Molecule - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Freeze-Drying Process Optimisation for a Small Molecule


Pharmaceutical Technology Europe
Volume 24, Issue 6


Table II
FDM measurements were repeated after one week of storage at room temperature to investigate potential instability of the solution that may lead to changes in Tg. Regarding the standard deviations, no clear difference between immediate measurements and experiments after one week of storage can be observed. It is important to note that at higher concentrations, the visual detection of collapse becomes more difficult. Due to the increased density of the sample and, therefore, reduced translucence, variations between replicate measurements increase.


Figure 2
Comparison of DSC and FDM data. Tg' and Tc are not identical as the measurement methodologies are different. Collapse describes a dynamic process because sublimation actually takes place during a FDM experiment, and the observed structural changes occur in the already dried matrix. In contrast, during the DSC measurement, the amorphous drug is in direct contact with ice without a drying process. Therefore, the experimental conditions of a FDM measurement better simulate those of a real freeze-drying run, and the structural changes can be visually observed. Moreover, Tg' values are commonly reported as midpoint while the collapse temperature mostly refers to the onset of collapse. To roughly estimate a 50% structural loss in the dried matrix (midpoint) and to simplify comparison to DSC data, Tc-50 was introduced as a calculated average of Toc and Tfc (8). Figure 2 illustrates the CFTs determined with both methods during the present study. As previously described in the literature (2, 8, 12), Tg' in the authors' study is lower than Toc, with greater difference at higher total solid content. For example, Toc of the 5% solution is about 2 °C higher, and at 30% total solid content, the difference amounts to approximately 4 °C compared to the midpoint Tg'. Taking Tc-50 into account, the gap ranges from 2.6 °C (5% w/v) to about 5 °C at 30% w/v for the measurement series directly after preparation. Regarding the fact that an increase of only 1 °C in product temperature during primary drying can reduce cycle time up to 13%, the application of Toc instead of Tg' clearly permits more space for cycle optimisation, especially at higher concentrations (13).

Conclusions

The results of this study show that even for the relatively simple solution of a pure small-molecule drug, the collapse temperature determined by FDM can be considered as the practically more relevant CFT for process development and optimisation. The direct observation of the collapse event and the width of the gap between Toc and Tfc can provide additional valuable information on the temperature tolerance of the sample. In the case of gentamicin sulphate, the temperature difference is not as big as it has been reported for protein formulations, indicating low robustness of the dried material in the microcollapse regime. Considering the great influence of small differences in product temperature on primary drying time and product morphology, the use of freeze-dry microscopy is a substantial contribution to efficiency and quality in the freeze-drying of small molecules.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here